Research programme: metastatic breast cancer therapy - Chugai

Drug Profile

Research programme: metastatic breast cancer therapy - Chugai

Alternative Names: CH 4893237

Latest Information Update: 22 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Biopharmaceuticals; Immusol
  • Developer Chugai Biopharmaceuticals; iTherX Pharmaceuticals
  • Class Estradiol congeners
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer metastases

Most Recent Events

  • 24 Aug 2007 This programme is still in active development
  • 26 Jan 2005 Data presented at the 27th Annual San Antonio Breast Cancer Symposium (SABCS-2004) have been added to the Cancer pharmacodynamics section
  • 04 Nov 2002 Chungai Pharmaceutical has been acquired by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top